ARCOXIA 60 MG TABLETS

국가: 이스라엘

언어: 영어

출처: Ministry of Health

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
26-09-2021
제품 특성 요약 제품 특성 요약 (SPC)
26-09-2021
공공 평가 보고서 공공 평가 보고서 (PAR)
18-08-2016

유효 성분:

ETORICOXIB

제공처:

ORGANON PHARMA ISRAEL LTD., ISRAEL

ATC 코드:

M01AH05

약제 형태:

FILM COATED TABLETS

구성:

ETORICOXIB 60 MG

관리 경로:

PER OS

처방전 유형:

Required

Manufactured by:

ORGANON LLC, USA

치료 그룹:

ETORICOXIB

치료 영역:

ETORICOXIB

치료 징후:

Arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis.

승인 날짜:

2013-10-31

환자 정보 전단

                                Page 1 of 9
רבוטקוא
2022
ה/דבכנ ה/אפור
ה/דבכנ ת/חקור :ןודנה
ו אפורל םינולעב ותבותכו ןרציה םשו
ותבותכו םושירה לעב ןוכדע
ל ןכרצ תובקעב לעב תרבעה
ה
םירישכת לש םושיר
מ -
MSD
ל
-
ORGANON
ראורבפמ ונתעדוהל ךשמהב
2022
מ לחה םושירה לעב תרבעה לע ,
-
01/03/2022
מ
קרמ תרבח
םהודו פראש
)
לארשי
-
1996
(
מ"עב
("MSD")
תרבחל
מ"עב לארשי המראפ ןונגרוא
(“ORGANON Pharma Israel Ltd.,”)
,
לש ןכרצלו אפורל םינולעב םיאבה
םייונישה ולח
.הטמ הלבטב םיטרופמה םירישכתה
•
ל הנוש םושירה לעב םש
-
עדי ריתע ,מ"עב לארשי המראפ ןונגרוא
1
אבס רפכ ,
•
ל הנוש ןרציה םש
-
ןונגרוא
LLC
ב"הרא יזר'ג וינ ,
ולעה
םינ
ולעהו אפורל
םינ
דרשמ לש טנרטניאה רתאבש תופורתה רגאמב
םוסרפל וחלשנ ןכרצל
:ליימב ,לארשי המראפ ןונגרוא תרבח
,םושירה לעבל הינפ ידי לע םיספדומ םלבקל
ןתינו ,תואירבה
organon.ra.israel@organon.com
.
םירישכתה לכ
פומ
םיצ
.מ"עב גולובונ תרבח י"ע
,הכרבב
ןמיש המלע
הנוממ תחקור
לארשי המראפ ןונגרוא רישכתה םש
תילגנאב רישכתה םש
תירבעב
הרוצ
קזוחו בכרה
היוותה
Aerius tablets
תוילבט סוירא
Tablets
Desloratadine 5mg
indicated in adults and
adolescents aged 12
years and older for the
relief of
symptoms
associated with:
- allergic rhinitis
- urticaria
Arcoxia 30 mg
Tablets
היסקוקרא
30
תוילבט ג"מ
Tablets
Etoricoxib 30 mg
Arcoxia tablets are
indicated for the
symptomatic relief of
osteoarthritis (OA).
Arcoxia 60 mg
Tablets
היסקוקרא
60
תוילבט ג"מ
Tablets
Etoricoxib 60 mg
Arcoxia 60 mg tablets are
indicated for the
symptomatic relief of
osteoa
                                
                                전체 문서 읽기
                                
                            

제품 특성 요약

                                [Organon] Proprietary
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
ARCOXIA
® 30 MG TABLETS
ARCOXIA
® 60 MG TABLETS
ARCOXIA
® 90 MG TABLETS
ARCOXIA
® 120 MG TABLETS
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 30, 60, 90 or 120 mg of etoricoxib.
Excipients with known effect:
30 mg tablet: 1.3 mg lactose (as monohydrate)
60 mg tablet: 2.7 mg lactose (as monohydrate)
90 mg tablet: 4.0 mg lactose (as monohydrate)
120 mg tablet: 5.3 mg lactose (as monohydrate)
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film-coated tablets (tablets).
30 mg tablets: Blue-green, apple-shaped biconvex tablets debossed
‘101’ on one side and
‘ACX 30’ on the other side.
60 mg tablets: Dark green, apple-shaped, biconvex tablets debossed
‘200’ on one side
and ‘ARCOXIA 60’ on the other side.
90 mg tablets: White, apple-shaped, biconvex tablets debossed
‘202’ on one side and
‘ARCOXIA 90’ on the other side.
120 mg tablets: Pale-green, apple-shaped, biconvex tablets debossed
‘204’ on one side
and ‘ARCOXIA 120’ on the other side.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
ARCOXIA
®
30 mg
for the symptomatic relief of osteoarthritis (OA).
ARCOXIA
®
60 mg
for the symptomatic relief of osteoarthritis (OA), rheumatoid
arthritis (RA) and ankylosing
spondylitis (AS).
ARCOXIA
®
90 mg
for the symptomatic relief of rheumatoid arthritis (RA) and ankylosing
spondylitis (AS).
For the short-term treatment of moderate pain associated with dental
surgery.
ARCOXIA
®
120 mg
for the symptomatic relief of the pain and signs of inflammation
associated with acute
gouty arthritis.
The decision to prescribe a selective COX-2 inhibitor should be based
on an assessment
of the individual patient's overall risks (see sections 4.3, and 4.4).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
As the cardiovascular risks of etoricoxib may increase with dose and
duration of exposure,
the shortest duration possible and the lowest effective daily do
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 아랍어 06-09-2020
환자 정보 전단 환자 정보 전단 히브리어 26-09-2021

이 제품과 관련된 검색 알림